

Survival Rate and Average Age of the Patients with Breast Cancer in Iran: Systematic Review and Meta-Analysis

M.H. YektaKooshali (BSc)¹, M. Esmailpour Bandboni (PhD)^{1 *2}, H. Sharami (PhD)³, Z. Alipour (BSc)¹

1.Student Research Committee, Faculty of Nursing, Midwifery and Paramedicine, Guilan University of Medical Sciences, Rasht, I.R.Iran

2.Department of Nursing, Guilan University of Medical Sciences, Rasht, I.R.Iran

3.Reproductive Health Research Center, Guilan University of Medical Sciences, Rasht, I.R.Iran

J Babol Univ Med Sci; 18(8); Aug 2016; PP: 29-40

Received: Feb 25th 2016, Revised: Jun 1st 2016, Accepted: Jul 27th 2016.

ABSTRACT

BACKGROUND AND OBJECTIVE: Breast cancer is one of the most common and worrying health problems in women around the world. In predicting of survival rate in patients with breast cancer several factors such as age, breed and spread of disease, stage of diagnosis and lymph node involvement are involved. This study was aimed to determine the mean age and survival rate of women with breast cancer in Iran.

METHODS: This systematic review and meta-analysis was based on searching in iranian databases as SID, Magiran, Irandoc, Noormag, IranMedex and Medlib and international databases as Ebsco, Cochrane, CEBM, Google Scholar, Scopus, Web of Sciences, Jama, were published 1990-2016. Researched keywords were, breast cancer, age, survival rate, Iran and compound of them. The obtained documents analyzed based on appropriate checklist through a random effects model.

FINDINGS: In 52 studies, 332991 samples were tested. Average of 5-years survival rate, and mean age of women with breast cancer estimated 68.84% in total (CI-95%: 64.9-72.72) and 48.59 years (CI-95%: 50.72-46.47). Lowest and the highest average of 5-years survival rate of them were calculated in northern of Iran 60.65%(CI-95%: 53.58-67.72) and in Tehran with 73.99%(CI-95%: 64.76-83.22), respectively. Lowest and highest average age of patients were calculated in North, 45.46(CI-95%: 35.10-55.83) years and in West with 49.83(CI-95%: 32.71-66.95) years.

CONCLUSION: Survival rate and mean age are tow essential variables in treatment management of breast cancer. These tow essential variables in north of Iran, were the lowest. Therefore, consider these factors and screening exam for early diagnosis are recommended.

KEY WORDS: Iran, Breast, Cancer, Neoplasm, Survival Rate, Age, Meta-analysis, Systematic Review.

Please cite this article as follows:

YektaKooshali MH, Esmailpour-Bandboni M, Sharami H, Alipour Z. Survival Rate and Average Age of the Patients with Breast Cancer in Iran: Systematic Review and Meta-Analysis. J Babol Univ Med Sci. 2016;18(8):29-40.

*Corresponding author: M. EsmailpourBandboni (PhD)

Address: Department of Nursing Rasht Guilan University of Medical Sciences, Rasht, Giluan, I.R.Iran

Tel: +98 13 42256263

E-mail: m_esmailpour@gums.ac.ir

Introduction

Breast cancer is one of the most common and worrisome health problems in the world (1-4) and includes 30% of female cancer (5, 6). Breast cancer is the second cause of death in developed countries and is the third leading cause of death in less developed countries (8, 7, 3) and approximately 41,000 women die from breast cancer in year (9,10). According to the World Health Organization predicts by 2050, up 2.3 million women will be diagnosed with breast cancer (11, 12). The incidence of breast cancer mortality was reported in the countries of northern Europe and North America the highest, and in Asian and African countries the lowest and in South America and southern Europe as average (13).

Aging, genetic predisposition, personal history of breast cancer, exposure to types of radiation, cigarette (14), geographic influences, number of pregnancies, late menopause, early menstruation, obesity (15) and first childbirth after age 30 could be as risk factors for breast cancer (19-16). There are various methods for the treatment of breast cancer, according to the grading, staging, physical condition of the patient and his wishes (16). Overall 5-year survival rate is considered as a criterion in the assessment of cancer services and the undertaken work representing the survival of patients with a type of cancer is in the fifth year of diagnosis (20).

In predicting survival in patients with breast cancer factors such as age (23-21), race (24, 25) and the spread of disease, diagnosis (28-26, 10) and lymph node involvement (29, 30) are involved. Age at menarche, age at first pregnancy and menopause are important dates influencing the occurrence of breast cancer in women (32, 31). The main goals of meta-analysis studies are the increased sample size due to the increased number of relevant studies, reduced difference in existing parameters and reduced confidence interval (34, 33). In fact, these studies are a vital link between research studies and decision-making at the bedside (35, 34).

Despite relatively high stats of breast cancer in the country (36, 16) and the importance of evaluating the survival rate and the average age of the patients involved in breast cancer to evaluate therapeutic strategies and better control of risk factors for breast cancer, there is no rough estimate of the average survival age of breast cancer in Iran. This study was conducted to review studies on breast cancer survival rate and the average age of the patients involved in the

entire country, from 1990 to 2016 using systematic review and meta-analysis.

Methods

This study is the first systematic review and meta-analysis to evaluate the survival rate and an average age of breast cancer patients involved in Iran from 1990 to 2016. This study is included all papers published in national and international journals, congress abstracts, conference papers, books, dissertations and reference sites. Articles were selected from internal databases such as SID, Magiran, Irandoc, Noormag, IranMedex and Medlib and international data banks including Ebsco, Cochrane, CEBM, Google Scholar, Scopus, Web of Sciences, Jama and Bandolier. The search of articles was done using Persian keywords: Iran, cancer, breast, age, survival, longevity and meta-analysis and using English keywords: Iran, Cancer, Neoplasm, Breast, Age, Survival and Meta-analysis and their compounds. Database searching was carried out with high sensitivity (High Sensitive Searching) by the researcher and senior expert in the field who were searching databases. At first, the titles of papers by the research team with the keywords were searched as it was 927. To avoid biased, the search was conducted by two researchers independently, and then the same query, and duplicates were excluded. Finally, based on mentioned inclusion and exclusion criteria, 52 article (5.6%) were analyzed (Fig 1). Then based on previous studies and surveys, the country was divided and studied into six geographical regions (38, 37).

Tehran was separately investigated because of the health, welfare and economic elite as well as a reference medical center for the other provinces. Checklist includes: name of author, year of publication, study location, time, sample size, the average age of the patients involved in breast cancer, the 1 to 5 and 10-year survival rate, survival rates based on the type of breast cancer and breast cancer stage. Because articles related to 2 to 4 years' survival and the survival rate based on the type and Stage of cancer was very low, these two factors were not examined.

Statistical analysis: In each study, after considering the age of the patients involved in breast cancer and survival rate as binomial distribution, the variance of the binomial distribution was calculated. Cochran test (Q) and I2 index were used to assess heterogeneity of

studies. Due to the heterogeneity of studies, the random effects model for combining the results of both studies was used. Data analysis was done using specialized software for meta-analysis (Cochrane Collaboration company) called Review Manager ver: 5.3.5 and $p < 0.05$ was considered significant.

Results

In this study, 927 papers were identified and after review and final assessment in accordance with designed checklist, a total 52 article containing 332,991 samples were listed. The number of articles with the subject of breast cancer survival rate was 26 and their sample size was 226,093 people. Of these, 125267 patients were (55.4 %) from Tehran, 3084 (1.36%) from the north, 3147 people (1.4%) from the south, 53855 people (23.8%) from Center, 1165 people (0.51%) from the west, 630 people (0.03%) from the east and 38812 people (17.16%) from national studies and not mentioned place (table 1). The number of articles with the subject of average age of patient with breast cancer was 41 and their sample size was 106898 people. Of these, 8358 patients (7.81%) from Tehran, 3028 patients (2.83%) from the north, 68315 cases (63.9%) from the south, 2231 cases (2.08%) from the center, 1429 people (1.33%) of the West, 8712 patients (8.15%) of the East of Iran and 14825 patients (13.86%) from national studies and not mentioned place (table 2). Based on the random effects model, 5-

year survival rate for breast cancer was calculated 68.84 percent (CI-95% from 64.95 to 72.72), respectively.

As the number of studies is insufficient data for 1-year and 10-year survival rate for breast cancer, these data of survival rate has not been analyzed. Also, the average age of the patients involved in breast cancer was calculated 48.59 years (CI-95% from 46.47 to 50.72). Due to the heterogeneity of the studies (heterogeneity index for five-year survival rate: $I^2 = 94\%$ and the mean age of the patients involved in breast cancer $I^2 = 0\%$), confidence intervals for individual studies and in terms of geographic regions and by year, based on a random effects model was estimated (Fig 2).

The lowest percentage of 5-year survival rate for breast cancer was reported in the north of the country 60.65% (CI-95% from 53.58 to 67.72) and highest in Tehran 73.99% (CI-95% from 64.76 to 83.22). 5-year survival rate for breast cancer in south of the country was calculated 68.65 percent (CI-95% from 66.08 to 71.22) using a random effects model which was very close to this amount in the country (68.84%). The lowest average age of the patients involved in breast cancer in the north of the country was 45.46 years (CI-95% from 35.10 to 55.83) and the highest in the West 49.83 years (CI-95% from 32.71 to 66.95) and the mean age of patients with breast cancer in center of the country was calculated 48.42 years using random-effects model (CI-95% from 43.55 to 53.28) (Fig 2).




Figure 1. Flowchart of entry procedures and criteria for selecting studies in systematic review and meta-analysis

Table 1. Profile of investigated studies related to 1, 5 and 10-year survival rate of breast cancer

Authors' name	Publication year	Place of study	Time of study	Sample size	1-year survival rate	5-year survival rate	10-year survival rate	Mean (month)
Akbari et al (39)	2006	Tehran	1995-97	154	95	76.6		
Fallahzadeh et al (36)	2014	Yazd	2002-07	200		70		
Fooladi et al (40)	2011	Ardebil	2003	161		51±0.05		
Haghighat et al (41)	2013	Tehran	1997-2006	623		87		
Yaghmaie et al (16)	2008	Semnan	1991-2001	50	86.9	58	47	
Vojdaninia et al (20)	2003	Tehran	2003	167	93	62±0.04		47.3
Makarian et al (42)	2013	Tehran	1999-2009	685				106.77
Moosavi Naeini (3)	2007	Tehran	1997-2007	242	100			
Fazeli et al (43)	2014	Markazi	2007-11	400	98	87		
Fardmal et al (44)	2013	Tehran	2004-11	542	96.8	68	31	109.7
Salehi et al (45)	2013	Tehran	2005-12	344		67.3		44.6
Bakhtiari et al (46)	2007	Babolsar		403				36
Movahedi et al (38)	2012	Top of northeast	2001-06	728	94.4±0.009	76.2±0.025		
Movahedi et al (38)	2012	North central	2001-06	625	95.2±0.005	75.3±0.015		
Movahedi et al (38)	2012	Center	2001-06	359	94.8±0.007	73.3±0.018		
Movahedi et al (38)	2012	East central	2001-06	437	91.9±0.014	69.6±0.036		
Movahedi et al (38)	2012	North	2001-06	294	96.3±0.007	69.6±0.028		
Movahedi et al (38)	2012	The lower part of the South West	2001-06	1974	95.2±0.01	68.9±0.032		
Movahedi et al (38)	2012	South Central	2001-06	221	96.4±0.013	67.4±0.052		
Movahedi et al (38)	2012	East	2001-06	430	95.3±0.01	65.7±0.046		
Movahedi et al (38)	2012	North west		1078	92.5±0.015	62.1±0.043		
Khadivi et al (47)	2012	Shahrkord		52200		62		
Akbari et al (48)	2008			441		81	77	
Rezaeian et al (49)	2009	North of Iran	2000-05	1148		58		
Moosavi et al (2)	2009	National review	1998-2005	36871		65-73		
Heidari et al (50)	2009	South of Iran	2001-06	863	97	67	45	
Gohari et al (51)	2006	Tehran	1990-2003	117				49.6
Vojdaninia et al (52)	2004	Tehran	1997	128		75		
Ghavam nasiri et al (53)	2005	Mashhad	1995-9	133		47.7		
Mosavi Naeini (54)	2009	Tehran	2009	242		89		
Rajaei fard et al (55)	2005	Shiraz	1993-2002	310		70		
Asadzadeh vostakolaei, et al (56)	2012	National	1999-2001	1500		72		
Akbari et al (57)	2014	National		122000		82		
Hedayati et al (58)	2014	Tehran	1998-2014	23		75		

*Listed numbers at the front of authors' names indicating the reference number.

Table 2. Characteristic of the investigated studies regarding to average age of breast cancer

Authors' name	Publication year	Place of study	Time of study	Sample size	The average age of breast cancer patient
Akbari et al (39)	2006	Tehran	1995-97	154	48.11±0.5
Fallahzadeh et al (36)	2014	Yazd	2002-2007	200	48.11±29.7
Fooladi et al (40)	2011	Ardebil	2003	161	45.12±5.3
Haghighat et al (41)	2013	Tehran	1997-2006	623	46.11±3.05
Yaghmaie et al (16)	2008	Semnan	1991-2002	50	51.14±5
Vojdaninia et al (20)	2003	Tehran	1997	167	47.13±2.5
Makarian et al (42)	2013	Tehran	1999-2009	685	47.11±9.08
Moosavi Naeini (3)	2007	Tehran	1997-2007	242	48.11±3.1
Fazeli et al (43)	2014	Markazi	2007-11	400	50.1±28.36
Fardmal et al (44)	2013	Tehran	2004-11	542	46.10±6.82
Salehi et al (45)	2013	Tehran	2005-12	344	49.10±9.93
Movahedi et al (38)	2012	The top of northwest	2001-06	728	49.12±83.36
Movahedi et al (38)	2012	North central	2001-06	625	50.12±9.28
Movahedi et al (38)	2012	central	2001-06	359	49.12±83.36
Movahedi et al (38)	2012	East central	2001-06	437	49.12±83.36
Movahedi et al (38)	2012	North	2001-06	294	49.12±83.36
Movahedi et al (38)	2012	The lower part of southwest	2001-06	1974	49.12±83.36
Movahedi et al (38)	2012	South central	2001-06	221	49.12±83.36
Movahedi et al (38)	2012	East	2001-06	430	49.12±83.36
Movahedi et al (38)	2012	North west	2001-06	1078	47.11±5.58
Heidari et al (50)	2012	South of Iran	2001-06	863	46.11±3.5
Gohari et al (51)	2006	Tehran	1990-2003	117	46.11±3.5
Asadzadeh vostakolaei et al (56)	2012	National	1999-2001	1500	46±12
Yavari et al (59)	2005	Tehran	2004	203	48.9±8.8
Ebrahimi et al (60)	2002	Tehran	1997-8	266	47.12±5.5
Fathinejad et al (61)	2004	Mashhad	2002	170	41.5±5.6
Pesaran et al (62)	2003	Shahrkord	2003	176	49.11±0.3
Talei et al (63)	1997	Shiraz	1994-5	12894	>53
Asadi et al (64)	1998	Bushehr	1996-7	2842	30-65
Mahbubi et al (4)	2004	Babol	1998-99	100	39.11±7.02
Dabiri et al (65)	2002	Kerman	1998-2000	75	50.1
Naderi et al (66)	2000	Kerman	1999	2000	20-98
Omranpour et al (67)	2003	Tehran	2000-01	100	29-76
Modir et al (68)	2001	Yazd	2001	110	19-64
Hasani esfahani et al (69)	2001	Tehran	2001	110	48.10±9.4
Abbas alizadeh et al (70)	2002	Tabriz	2001	842	>30
Zakavi et al (71)	2004	Mashhad	2002-03	110	20-79
Chokar et al (72)	2000	Ilam	1998	264	>20
Ramezani et al (73)	2001	National	2000	13325	20-49
Dadkhah et al (74)	2002	Ardebil	2001	150	20-50
Abedzadeh et al (75)	2003	Kashan	2001	400	29.7±7.9
Hajimahmoodi et al (76)	2002	Tehran	2001	410	32.9±9.5
Mahoori et al (77)	2003	Shiraz	2002	1000	>35
Harirchi et al (78)	2005	Tehran	1996-2000	2343	48.8
Nafisi et al (50)	2012	Tehran	2010	650	40.9±72.58
Almasi Nokiae et al (80)	2005	Kermanshah	2000-03	48742	45.9±66
Bakhtiari et al (46)	2007	Babolsar	2007	403	45.12±97.03
Montazeri et al (81)	2008	Tehran	2008	1402	43.14±4.4
Baeradeh et al (82)	2014	Khorasan razavi	2008	5617	18±61.5




Figure 2. The estimated 5-year survival rate (left) and average age (right) in patients with breast cancer and their 95% confidence interval in the investigated studies based on authors' name and geographical regions separately (six regions: Tehran, north, south, Central, west and east) in order of year based on a random effects model. The left graph midpoint of each segment is the estimation of the 5-years survival rate, and in the right graph is the average age of the patients involved in breast cancer and the length of segment is 95% confidence interval in each geographic region. Diamond symbols in the left graph shows the overall 5-year survival rate and in the right graph shows the mean age of patients.

Discussion

This is the first systematic review and meta-analysis study aimed to investigate the survival rate and the average age of the breast cancer patients in Iran. In all 52 article, the 5-year survival rate of breast cancer in women was estimated 68.84% (CI-95% from 64.95 to 72.72) and the mean age of the breast cancer patients was calculated 48.59 years (CI-95% from 46.47 and 50.72). Protani and colleagues in their systematic review concluded that the survival rate of

women with breast cancer decreases along with obesity increased body mass (1.47 and 1.21: CI-95%; HZ =1.33) (83). Radiation therapy can decrease also 10-year mortality risk of 35% to 19.3% and 15-year mortality risk from 25.2% to 21.4%, respectively (84). Results of Iranian studies (38, 2) with a survival rate of 65-72 percent, as well as the results of foreign studies (85-89) a survival rate of 72-53% confirm the results of this study. According to the report of National

Cancer Institute of America, 5-year survival rate for breast cancer based on stage 0, 1, 2, 3, 4 are 100, 100, 93, 72 and 22 percent, respectively (90).

This difference could be due to gross disparities in health indices of the community. Results for Iranian Studies (56, 38), with a mean age range 46 ± 12 - 49.83 ± 12.36 years, although exactly is not match to the average age of the present study, but accounted for the confidence interval of this study. In addition, the results of foreign studies (92, 91), with an average age of 58.8 ± 12.7 years, was corresponded with these results. Differences in health indicators can be one of the most important factors is the difference in the results of the above countries. Key and colleagues also showed an increased risk of breast cancer with age. During pregnancy the risk of breast cancer is higher and after that (menopause), after 50 years old was reported slower (93). The total sample size in this study were 332991 people.

The heterogeneity in 5-year survival rate of breast cancer was 94% and the mean age of patients involved in breast cancer 0% was obtained. In study of 5-year survival rate for breast cancer, it is assumed that the observed differences are due to different sampling as well as differences in the measured parameters in different societies. Based on the conducted studies, the lowest 5-year survival rate for breast cancer was reported in the north of the country 60.65% (CI-95% from 53.58 to 67.72) and highest in Tehran 73.99% (CI-95% of 64.76 to 83.22). The lowest average age of the breast cancer patients in the north of the country was obtained 45.46 years (CI-95% from 35.10 to 55.83) and highest average age in the West was 49.83 years (CI-95% from 32.71 to 66.95), respectively. According to the report of Ministry of Health and Medical Education (2011), the percentage of breast cancer in northern provinces is higher compared to other provinces (7).

However, given the importance of this issue, no study was done in Guilan province as one of the northern provinces. Some studies in the north of the country have reported a higher incidence of cancer (especially gastric cancer and esophageal squamous cells) compared to other parts of the country (94-96, 37). In this regard, in accordance with development plan policies and national health officials, healthcare, large cohort studies on cancer types in the north of the country are running by the researchers.

These studies will be discussed the major causes of a higher incidence of cancer than other places in the

north of the country as well as methods of screening, prevention and treatment. According to studies, the average age and survival rate are two key factor in the management of patients with breast cancer. According to previous studies, exploration and consideration of breast cancer using different ways in the early stages of the disease and prior to lymph node involvement can cause a significant reduction in mortality and health of women (97, 89, 28).

Investigations also indicated an increased awareness and community education, the establishment of screening programs (breast self-examination (98), clinical breast examination, mammography, ultrasound and magnetic resonance imaging (MRI)) (99) and providing diagnostic and therapeutic facilities for the public especially in lower levels of society is associated with the early stage diagnosis (100-104). Thus providing the above-mentioned cases in each province based on the presence of risk factors for early detection and effective treatment of breast cancer can be placed in the health policy agenda.

Limitations: Due to a systematic review of studies, regular and systematic review of evidence, summing up of different results and providing a general interpretation resulting from studies and create a vital link between research studies and important decisions at the bedside are the points of this study. In contrast, indetermination of the qualitative value of these studies, individuals referred to treatment centers were not randomly selected, the lack of survival rate review based on breast cancer stage, the more studies from Tehran province compared to other provinces are the limitations of this study.

In addition, because the average age of the patients referred to the hospital was considered and the exact average age of breast cancer was not available due to misdiagnosis and lack of timely referral, can be considered as other limitations of this study. Breast cancer is preventable and early detection among all cancers that applying specific strategies can reduce the delay and provide effective treatment to increase patients' survival, reduce mortality and improve quality of life of patients. The average age and survival rate of breast cancer are two important factors in the management of these patients.

In addition, because the average age of the patients referred to the hospital was considerable and the exact average age of breast cancer due to misdiagnosis and timely referral was not available, can be considered as

limitations of this study. Therefore, further studies in this area can improve the health of women and mothers in the country's socio-economic cycle and can be taken effective steps in achieving to the goal of healthy humans' sustainable development.

Acknowledgments

Hereby, we would like to thank Guilan University of Medical Sciences supporting us to publish the first systematic review and meta-analysis of breast cancer in Iran.

References

1. Screening for Breast Cancer. WHO; 2016. Available from: <http://www.who.int/cancer/detection/breastcancer/en/>.
2. Mousavi S, Montazeri A, Mohagheghi M, Jarrahi A, Harirchi I, Najafi M, et al. Breast cancer in Iran: an epidemiological review. *Breast J*. 2007;13(4):383-91.
3. Parkin D, Läärä E, Muir C. Estimates of the worldwide frequency of sixteen major cancers in 1980. *Int J Cancer*. 1988;41(2):184-97.
4. Mahboobi A, Alvandi S, Alizadeh Navaei R. An analytical survey on breast lesions in mammography. *J Babol Univ Med Sci*. 2004;6(2):52-5. [In Persian].
5. Dean T, Armando E. Breast cancer. Novak J, Berek J, editors. *Novak's gynecology*. 13th. Philadelphia: Lippincott William & Wilkins; 2002.
6. Harris JR, Lippman ME, Morrow M, Osborne CK. *Diseases of the Breast*: Wolters Kluwer, 5th. United States: Health; 2014.
7. Aghajani H EK, Goya M, Ramezani R, Modirian M, NADALI F. National cancer registry report 2008. *Center Dis Control*. 2011.
8. Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin*. 2011;61(2):69-90.
9. Harirchi I, Ebrahimi M, Zamani N, Jarvandi S, Montazeri A. Breast cancer in Iran: a review of 903 case records. *Pub Health*. 2000;114(2):143-5.
10. Winer EP, Morrow M, Osborn CK, Harris JR. Chapter 37: Cancer of the breast in Devita Jr VT, Helman S, Rosenberg SA. *Cancer principles and practice of oncology*. 6th. Williams and Wilkins lippincott: Philadelphia, 2001.
11. Hortobagyi GN, de la Garza Salazar J, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. *Clin Breast Cancer*. 2005;6(5):391-401.
12. YektaKooshali M, Esmaeilpour-Bandboni M, Ramezani A, editors. The Scientific Production and Mapping of researchers in Breast Cancer during 1985– 2015 in Iran in *Web of Sciences*. 11th International Breast Cancer; 2016: 11th International Breast Cancer: http://ibcc.sbm.ac.ir/uploads/454_3334_1456829171552_1394.pdf.
13. Kelsey J. A review of the epidemiology of human breast cancer. *Epidemiol Rev*. 1979;1(1):74-109.
14. Amini Sani N, Shamshir Garan M, Ghavam Nasiri M, Setayesh Y. The effect of active and passive smoking associated with breast cancer. *J Babol Univ Med Sci*. 2005;7(1):63-8. [In Persian].
15. Hajian K, Gholizadehpasha A, Bozorgzadeh S. Association of obesity and central obesity with breast cancer risk in pre and postmenopausal women. *J Babol Univ Med Sci*. 2013;15(3):7-15. [In Persian]
16. Yaghmaei S, Bani Hashemi G, Ghorbani R. Survival rate following treatment of primary breast cancer in Semnan, Iran (1991-2002). *Koomesh*. 2008;9(2):111-6. [In Persian].
17. Bland KI, Beoken SW, Copeland EM, The Breasts In: Brunicki FC, Anderson DK, Billea TR, Dunn DL, Hunter JG, Pollock RE, editors. *Schwartz's Principles of Surgery*, 8th. New York: McGraw-Hill; 2005;453-99.
18. Iglehart JD, Kaelin CM. Diseases of the breast. In: Townsend CM, editor. *Sabiston textbook of surgery, the biological basis of modern surgical practice*. 6th. Philadelphia: WB Saunders; 2001. p.555-90.
19. Hajizadeh N, Pourhoseingholi M, Emadedin M, Baghestani A, Fazeli Z. Incidence Rate of Breast Cancer In Iranian Women, Trend Analysis From 2003 to 2009. *Int J Pharma Biomed Sci*. 2015;4(3):107-12.
20. Vahdaninia M, Harirchi A, Montazeri A. Evaluation of 5-year survival in women with breast cancer who referred to Imam Khomeini hospital: a prospective study. *Payesh Health Monit*. 2003;2(2):141-8. [In Persian]
21. Albain K, Allred D, Clark G. Breast cancer outcome and predictors of outcome: are there age differentials? *J Natl Cancer Inst Monogr*. 1994;16:35-42.
22. Walker R, Lees E, Webb M, Dearing S. Breast carcinomas occurring in young women 35 years are different. *Br J Cancer*. 1996;74(11):1796-800.
23. Komran N, Jensen M, Wohlfahrt J, Mouridsen H, Anderson P, Melbye M. Factors influencing the effect of age on prognosis in breast cancer: population based study. *BMJ*. 1998;320(7233):447-9.
24. Edison M, Becker T, Wiggins C. Breast cancer among hispanics, American Indian and non hispanic whites in New Mexico. *Int J Epidemiol*. 1994;23(2):231-6.
25. Boyer-Chamard A, Taylor TH, Anton-Culver H. Survival differences in breast cancer among racial/ethnic groups: a population-based study. *Cancer Detect Prev*. 1999;23(6):463-73.
26. Byrne C, Smart C, Chu K, Hartman W. Survival advantage differences by age. Evaluation of the extended follow-up of the breast cancer detection demonstration project. *Cancer*. 1994;74(1):301-10.
27. Nab H, Hop W, Crommelin M, Kluck H, Vander Heijden L, Coebergh J. Changes in long term prognosis for breast cancer in a Dutch cancer registr. *BMJ*. 1994;309(6947):83-6.
28. Bunderd NJ. Prognostic and predictive factors in breast cancer. *Cancer Treat Rev*. 2001;27(3):137-42.
29. Fernö M. Prognostic factors in breast cancer: a brief review. *Anticancer Res*. 1998;18(3C):2167-71.

- 30.Tabar L, Duffy S, Vitak B, Chen H, Prevest T. The natural history of breast carcinoma: what have we learned from screening?. *Cancer*. 1999;86(3):449-53.
- 31.Treves N, Holleb A. A report of 549 cases of breast cancer in women 35 years of age or younger. *J Am Coll Surg*. 1958;109(3):271-83.
- 32.Nugent P, O'Connell T. Breast cancer and pregnancy. *Arch Surg*. 1985;120(11):1221-4.
- 33.Saffari M, Sanaeinasab H, Pakpour A. How to Do a Systematic Review Regard to Health: A Narrative Review. *J Health Edu Health Promot*. 2013;1(1):51-61.
- 34.Liberati A, Taricco M. How to do and report systematic reviews and meta-analysis. In Franchignoni F. *Research in Physical & Rehabilitation Medicine*. Pavia: Maugeri Foundation Books; 2010, p. 137-164.
- 35.Cook D, Mulrow C, Haynes R. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med*. 1997;126:376-80.
- 36.Fallahzadeh H, Momayyezi M, Akhundzardeini R, Zarezardeini S. Five year survival of women with breast cancer in Yazd. *Asian Pac J Cancer Prev*. 2014;15(16):6597-601.
- 37.Yarhousseini A, Sharifzadeh L, Delpisheh A, Veisani Y, Sayehmiri F, Sayehmiri K. Survival rates for Esophageal cancer in Iran: a systematic review and meta-analysis. *Iran J Cancer Prev*. 2014;7(2):61-5.
- 38.Movahedi M, Haghighat S, Khayamzadeh M, Moradi A, Ghanbari-Motlagh A, Mirzaei H, et al. Survival rate of breast cancer based on geographical variation in iran, a national study. *Iran Red Crescent Med J*. 2012;14(12):798-804.
- 39.Akbari M, Mirzaei H, Soori H. 5 year survival of breast cancer in Shohada-e- Tajrish and Jorjani hospitals. *Hakim Res J*. 2006;9(2):39-44.[In Persian].
- 40.Fouladi N, Amani F, Harghi Afshan S, Nayebyazdi N. Five year survival of women with breast cancer in Ardabil, north-west of Iran. *Asian Pac J Cancer Prev*. 2011;12(7):1799-801.
- 41.Haghighat S. Survival rate and its correlated factors in breast cancer patients referred to Breast Cancer Research Center. *Iran J Breast Dis*. 2013;6(3):28-36.[In Persian].
- 42.Makarian F, Makarian S, Ramezani A. Relations of disease-free survival and overall survival with age and primary metastases in patients with breast cancer. *J Isfahan Med Sch*. 2013;31(225):112-20.[In Persian].
- 43.Fazeli Z, Najafian-Zade M, Eshtrati B, Almasi-Hashiani A. Five-year evaluation of epidemiological, geographical distribution and survival analysis of breast cancer in Markazi Province, 2007-11. *J Arak Univ Med Sci*. 2014;16(80):72-9.
- 44.Fardmal J, Mafi M, Sadighi-Pashaki A, Karami M, Roshanaei G. Factors affecting survival in breast cancer patients referred to the darol aitam-e mahdiah center. *J Zanjan Univ Med Sci*. 2013;22(93):105-15.[In Persian].
- 45.Salehi M, Gohari M, Vahabi N, Zayeri F, Yahyazadeh S, Kafashian M. Comparison of artificial neural network and cox regression models in survival prediction of breast cancer patients. *J Ilam Univ Med Sci*. 2013;21(2):120-8.[In Persian].
- 46.Bakhtiari A, Hajian K. Five year disease-free survival rate in breast cancer patients in Rajaii Hospital, Babolsar. *J school pub health*. 2007;5(2):53-9.[In Persian].
- 47.Khadivi R, Harirchi I, Akbari M. Ten year breast cancer screening and follow up in 52200 women in Shahre-Kord, Iran (1997-2006). *Iran J Cancer Prev*. 2008;1(2):73-7.
- 48.Akbari A, Akbari M, Khaymzadeh M, Khoshnevis S, Nafisi N. Five and ten years survival in breast cancer patients mastectomies vs. breast conserving surgeries personal experience. *Iran J Cancer Prev*. 2008;1(2):53-6.
- 49.Rezaianzadeh A, Peacock J, Reidpath D, Talei A, Hosseini S, Mehrabani D. Survival analysis of 1148 women diagnosed with breast cancer in Southern Iran. *BMC Cancer*. 2009;9(9):168.
- 50.Heydari T, Mehrabani D, Tabei S, Azarpira N, Vakili M. Survival of breast cancer in southern Iran. *Iran J Cancer Prev*. 2012;2(1):51-4.
- 51.Gohari M, Mahmoudi M, Mohammed K, Pasha Y, Khodabakhshi R. Disease free survival and metastases pattern in breast cancer patients after mastectomy: An application of stratified Markov model. *Int J Cancer Res*. 2006;2:8-10.
- 52.Vahdaninia M, Montazeri A. Breast cancer in Iran: a survival analysis. *Asian Pac J Cancer Prev*. 2004;5(2):223-5.
- 53.Ghavam-Nasiri M, Anvari K, Nowferesti G, Silanian-Toosi M. Locally advanced breast cancer: An experience in Mashhad, North-East of Iran, 1995-1999. *Arch Iranian Med*. 2005;8(3):206-10.
- 54.Mosavi Naeini S, Mofid B, Mohebbi H, Mehmannaavaz M, Khushini S. Comparison of local recurrence, metastasis and survival between the two surgical methods for the treatment of clinical stage I and II breast cancer. *kowsar med J*. 2009;14(2):89-94.[In Persian].
- 55.Rajaeifard A, Talei A, Baneshi M. Survival analysis models for breast cancer patients in Shiraz, 1993-2002. *J Med Res*. 2005;3(4):41-50.
- 56.Asadzadeh Vostakolaei F, Broeders MJ, Rostami N, Van Dijk Jos A, Feuth T, Kiemeney Lambertus A, et al. Age at diagnosis and breast cancer survival in iran. *Int J Breast Cancer*. 2012;8. file:///C:/Users/dd/Downloads/517976.pdf.

57. Akbari M, Khayamzadeh M, Zeinali Z, Mohammadi G, Hadizadeh M, Samsami M, et al., editors. Breast Cancer in Iran; from Epidemiology, Clinicopathological and Biomarker Feature. 7th breast cancer congress 2014; Iran: Breast Cancer Research Centre.
58. Hedayati Godarzi A, Hedayati F, Mokarram GZ, Hedayati A, editors. Management of breast cancer during pregnancy and review of 23 treated cases in our clinic and Ostad alinasab hospital in Tabriz (north west of Iran). 7th breast cancer congress 2014; Iran: Breast Cancer Research Centre.
59. Yavari P, Mosavizadeh M, Sadrol-Hefazi B, Mehrabi Y. Reproductive characteristics and the risk of breast cancer—a case-control study in Iran. *Asian Pac J Cancer Prev*. 2005;6(3):370-75.
60. Ebrahimi M, Vahdaninia M, Montazeri A. Risk factors for breast cancer in Iran: a case-control study. *Breast Cancer Res*. 2002;4(5):1-4.
61. Fathinajafi T, Jabarzadehgangeh S, Mojahedirezaei S, Mazlom S. Assessment of Certain Breast Cancer Risk Factors During Reproductive Age in Women in Mashhad(2002-2003). *Iran Med J*. 2004;42:577-85.
62. Pesaran Z, Rezaei A, Tavakoloi R, Siadat A. Evaluation of breast cancer risk factors for using in hormone replacement therapy of corticosteroid- treated post-menopausal women. *Shahrekord Univ Med Sci*. 2003;2(5):70-5 [In Persian].
63. Talei A, Sadeghi-Hassanabadi A, Saalabian J, al. e. A preliminary report on breast cancer screening program in Shiraz southern Iran. *Iran J Med Sci*. 1997;22:148.
64. Assadi K, Ovjee M, Vahdat S, Shams S, Hghshenas M, Poursalimi S. Breast cancer screening in Bushehr port population aged 30-65 years. *South Med J*. 1998;1:217-22.
65. Dabiri S, Sedighi B. Sensitivity and specificity of FNA in women breast mass. *Hamadan Med J*. 2002;9(2):5-10 [In Persian].
66. Naderi T, Bahrampoor A. Determination of sensitivity and specificity of breast tumor diagnosis by health care auxiliaries (Behvarz). *Kerman Med J*. 2000;7(2):73-8 [In Persian].
67. Omranpoor R, Haghshenas S, Guiti M. Efficacy of axillary ultrasonography in preoperative evaluation of nodal metastases in breast cancer. *Tehran Med J*. 2003;61(5):359-63 [In Persian].
68. Modir A, Mirshamsi M, Hashemian M. FNA in breast tumors and compare with gross pathology. *Yazd Med J*. 2001;9:28-31. [In Persian]
69. Hasaniessfahani M, Mousavi S, Azargashb A. Efficacy of FNA for detecting Breast mass. *Pejouhandeh*. 2001;6:527-29. [In Persian]
70. Abbasalizadeh S, Abbasalizadeh F, Sahaf F, Navaei N. Pre-valence of breast cancer in north west of Tabriz. *Iranian J Obstetr Gyn*. 2002;5:54-7.
71. Zakavi S, Mehrabibahar M, Hadadiaval M. Efficacy of breast scan with TC-MIBI for breast mass detection. *Mashhad Med J*. 2004;47:141-36 [in Persian].
72. Joka F, Ghyasi N. Knowledge, attitude and practice of Ilamoan women about breast cancer. *Ilam Med J*. 2000;9:29-34 [In Persian].
73. Ramezani Tehrani F, Kazem M, Baroti E. Knowledge, attitude and practice of Iranian women 20-49 years old on Breast Cancer. *Teb Tazkiyeh*. 2001;42:30-7. [In Persian]
74. Dadkhah B, Mohammadi M. Knowledge, attitude and practice of Ardebilian women about BSE in 2001. *Ardebil Med J*. 2002;1:15-20. [In Persian]
75. Abedzadeh M, Sadat Z, Saberi F. Knowledge, attitude and practice of women who refer to rural health centers of Kashan about breast cancer and its case findings methods in 2001. *Feiz Med J*. 2003;7:85-92. [In Persian]
76. Haji-Mahmoodi M, Montazeri A, Jarvandi S, Ebrahimi M, Haghighat S, Harirchi I. Breast self-examination: knowledge, attitudes, and practices among female health care workers in Tehran, Iran. *Breast J*. 2002;8:222-5.
77. Mahori K, Sadeghi Hasanabadi A, Talei A. Knowledge and practice of women who refer to rural health centers of Shiraz about breast cancer screening. *Hormozgan Med J*. 2003;7. [In Persian]
78. Harirchi I, Ghaem-Maghami F, Karbakhsh M, Moghimi R, Mazaheri H. Patient delay in women presenting with advanced breast Cancer, a study from Iran. *Pub Health*. 2005;119:885-91.
79. Nafissi N SM, Motamedi MK, Akbari ME. A survey of breast cancer knowledge and attitude in Iranian women. *J Can Res Ther*. 2012;8:46-9.
80. Almasi nokiani F, Akbari H, Madani S, Izadi B, Emami A. Incidence of breast sample pthology reports in iran(Kermanshah)2001-2004. *J Kermanshah Univ Med Sci*. 2005;8(2):28-3.[In Persian]
81. Montazeri A, Vahdaninia M, Harirchi I, Harirchi A, Sajadian A, Khaleghi F, et al. Breast cancer in Iran: need for greater women awareness of warning signs and effective screening methods. *Asia Pac Fam Med*. 2008;7(1):6.
82. Ba Eradeh N, Mirzaei M, Zamani M. Epidemiology of Breast Cancer on Khurasan razavi in 2008. *Med J Mashad Univ Med Sci*. 2014;57(8):926-31.[In Persian]
83. Protani M, Coory M, Martin JH. Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis. *Breast Cancer Res Treat*. 2010;123(3):627-35.[In Persian]

- 84.(EBCTCG)* EBCTCG. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10801 women in 17 randomised trials. *Lancet*. 2011;378(9804):16-1707.
- 85.Demers AA, Turner D, Mo D, Kliewer EV. Breast cancer trends in Manitoba: 40 years of follow-up. *Chronic Dis Can*. 2005;26(1):13-9.
- 86.Fisch T, Pury P, Probst N, Bordoni A, Bouchardy C, Frick H, et al. Variation in survival after diagnosis of breast cancer in Switzerland. *Ann Oncol*. 2005;16:1882-8.
- 87.Ben Gobrane H, Fakhfakh R, Rahal K, Ben Ayed F, Maalej M, Ben Abdallah M, et al. Breast cancer prognosis in Salah Azaiez Institute of Cancer, Tunis. *East Mediterr Health J*. 2007;13:309-18.
- 88.Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S. The impact of bilateral breast cancer on the prognosis of breast cancer: a comparative study with unilateral breast cancer. *Breast Cancer*. 2005;12:196-202.
- 89.Marrazzoa A, Taormina P, David M, Riili I, Casa L, Catalano F, et al. Survival of breast cancer patients, Our experience. *Chir Ital*. 2007;59:313-8.
- 90.Cancer Information services: American cancer society. 2016 [cited 01/15/2016]. Available from: <http://www.cancer.org/cancer/breastcancer>
- 91.Bradshaw P, Ibrahim J, Khankari n, Cleveland R, Abrahamson P, Stevens J, et al. Post-diagnosis physical activity and survival after breast cancer diagnosis: The long island breast cancer study. *Breast Cancer Res Treat*. 2014;145:735-42.
- 92.Williams P. Significantly greater reduction in breast cancer mortality from post-diagnosis running than walking. *Int J Cancer*. 2014;135:1195-202.
- 93.Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. *Lancet Oncol*. 2001;2(3):133-40.
- 94.Jaffari E, Pourshams A, Khademi H, Sajadi A, Fazel A, Gogalani G, et al. Report on the first phase of 50,000 Golestan cohort, prospective study of risk factors for cancer and other chronic diseases in the North East of Iran. *Diges J*. 2010;14(1):7-14.
- 95.Shafieezadeh T, Holakuei Naieni K, Fotuhi A, Mahmoodi M. Familial aggregation of esophageal cancer in Babol district in the north of Iran. *sjsph*. 2006;4 (1):57-64.
- 96.Shafigh E, Siadati S, Shefaei S. The epidemiological study of cancer in hospitals of Babol Medical University, 1990-2002. *J Babol Univ Med Sci*. 2005;7(3):73-8. [In Persian]
- 97.Yang M, Rong T, Huang Z, Zeng C, Long H, Fu J, et al. Clinical analysis of resectable breast cancer: a report of 6263 cases. *Ai Zheng J*. 2005 Mar;24:327-31.
- 98.Karimi H, Sam S. Effect of breast self-examination (BSE) education on increasing women's knowledge and practice, Ramsar. *J Babol Univ Med Sci*. 2005;7(3):61-8.
- 99.American Cancer Society. breast cancer facts & figures 2013-2014.: American Cancer Society, Inc.; 2013 [cited 2014 March 9]. Available from: <http://www.cancer.org/acs/groups/content@research/documents/document/acspc-042725.pdf/>.
- 100.Hussain S, Altieri A, Sundquist J, Hemminiki K. Influence of education level on breast cancer risk and survival in Sweden between 1990 and 2004. *Int J Cancer*. 2008;122 (1):165-9.
- 101.Li C. Breast cancer epidemiology: Springer; 2010. p. 401
- 102..Sant M, Francisci S, Capocaccia R, Verdecchia A, Allemani C, Berrino F. Time trends of breast cancer survival in Europe in relation to incidence and mortality. *Int J Cancer*. 2006;119(10):2417-22.
- 103.YektaKooshali MH, Esmaeilpour-Bandboni M, Ramezani A. Scientific outputs of researchers in the field of ethics of health services in iran in the web of sciences during 2008-2015 as the scientific structure mapping. 4th Iran Med Ethics congress, Tehran. 2016:493. [In Persian]
- 104.YektaKooshali MH, Esmaeilpour-Bandboni M, Ramezani A. The scientific production and scientific mapping of world researchers in radiotherapy in iran during 1999 – 2015 in web of sciences. 1st National Congress of Paramedical Students. Poster 3-75. Available from: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=jBw15MoAAAAJ&citation_for_view=jBw15MoAAAAJ:GnPB-g6toBAC.